Methylphenidate transdermal - Noven Pharmaceuticals

Drug Profile

Methylphenidate transdermal - Noven Pharmaceuticals

Alternative Names: Daytrana; Methylphenidate transdermal system; MethyPatch; MTS

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Noven Pharmaceuticals
  • Class Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 25 Mar 2014 Discontinued - Phase-III for Attention-deficit hyperactivity disorder in USA (Transdermal)
  • 02 Oct 2010 Noven acquires global rights to methylphenidate transdermal from Shire
  • 18 Aug 2010 No development reported - Phase-III for Attention-deficit hyperactivity disorder in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top